Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 301K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Spencer, S. D. Articles by Aguet, M. Search for Related Content PubMed PubMed Citation Articles by Spencer, S. D. Articles by Aguet, M. Social Bookmarking                            What's this?

Articles

Susan D. Spencer^*, Francesco Di Marco, Jeff Hooley^*, Sharon Pitts-Meek^*, Michele Bauer^*, Anne M. Ryan^*, Bernard Sordat, Verna C. Gibbs, and Michel Aguet

From the ^* Genentech Inc., South San Francisco, California 94080; the Swiss Institute for Experimental Cancer Research, 1066 Epalinges s/Lausanne, Switzerland; and the Department of Surgery, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121

The orphan receptor CRF2-4 is a member of the class II cytokine receptor family (CRF2), which includes the interferon receptors, the interleukin (IL) 10 receptor, and tissue factor. CRFB4, the gene encoding CRF2-4, is located within a gene cluster on human chromosome 21 that comprises three interferon receptor subunits. To elucidate the role of CRF2-4, we disrupted the CRFB4 gene in mice by means of homologous recombination. Mice lacking CRF2-4 show no overt abnormalities, grow normally, and are fertile. CRF2-4 deficient cells are normally responsive to type I and type II interferons, but lack responsiveness to IL-10. By 12 wk of age, the majority of mutant mice raised in a conventional facility developed a chronic colitis and splenomegaly. Thus, CRFB4 mutant mice recapitulate the phenotype of IL-10–deficient mice. These findings suggest that CRF2-4 is essential for IL-10–mediated effects and is a subunit of the IL-10 receptor.

Part of this work was supported by National Institutes of Health grant R29 DK-48748 (to V.C. Gibbs).

Address correspondence to Michel Aguet, Swiss Institute for Experimental Cancer Research (ISREC), 155, Ch. des Boveresses, 1066 Epalinges s/Lausanne, Switzerland. Phone: 41-21-692-5918; Fax: 41-21-652-6933; E-mail: michel.aguet{at}isrec.unil.ch

¹ Abbreviations used in this paper: CRF2, class II cytokine receptor family; ES, embryonic stem; LIF, leukemia inhibitory factor; TF, tissue factor.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Glocker, E.-O., Kotlarz, D., Boztug, K., Gertz, E. M., Schaffer, A. A., Noyan, F., Perro, M., Diestelhorst, J., Allroth, A., Murugan, D., Hatscher, N., Pfeifer, D., Sykora, K.-W., Sauer, M., Kreipe, H., Lacher, M., Nustede, R., Woellner, C., Baumann, U., Salzer, U., Koletzko, S., Shah, N., Segal, A. W., Sauerbrey, A., Buderus, S., Snapper, S. B., Grimbacher, B., Klein, C. (2009). Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor. NEJM 0: NEJMoa0907206v1-1 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS